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Seven-Year Follow-Up of a Juvenile Female with Papillary 
Thyroid Carcinoma with Poor Outcome, BRAF Mutation and 
Loss of Expression of Iodine-Metabolizing Genes
ABSTRACT
Background: Recent studies reported that BRAF V600E mutation, the most 
prevalent genetic event found in papillary thyroid carcinoma, is an indepen-
dent poor prognostic marker. Additionally, it correlates with a less differenti-
ated tumor stage due to reduced expression of key genes involved in iodine 
metabolism. We previously described a patient with BRAF V600E mutation in 
primary tumor and a new mutation (V600E+K601del) in the matched-lymph 
node metastases. In the present study we report an unusual clinical behavior 
of PTC and correlate with BRAF mutational status and level of expression of 
TSHR and NIS. Methods: Quantitative PCR (qPCR) was used to evaluate the 
NIS and TSHR level of expression in matched papillary thyroid carcinoma and 
adjacent normal tissue. Results: In this study, we presented a seven-year fol-
low up of a juvenile papillary thyroid carcinoma patient who had an aggres-
sive tumor harboring BRAF mutation, and failed to conventional therapy. We 
found a markedly decrease of NIS and TSHR expression in primary PTC com-
pared to adjacent normal thyroid tissue. Conclusion: Our fi ndings suggest 
that BRAF mutational status and decreased NIS and TSHR expression in this 
patient may reduce radioiodine uptake and lead to a negative response to 
radioiodine therapy. (Arq Bras Endocrinol Metab 2008; 52/8:1313-1316)
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RESUMO
Sete Anos de Seguimento de uma Paciente Jovem com Carcinoma Papílfero 
de Tireóide e Mutação de BRAF e Perda de Expressão de Genes do Metabo-
lismo de Iodo.
Introdução: Estudos recentes demonstraram que a mutação V600E no gene 
BRAF é o evento genético mais freqüentemente encontrado em carcinoma 
papilífero da tiróide e um marcador de prognóstico independente. Adicional-
mente, esta alteração genética tem sido correlacionada com a redução de ex-
pressão de genes envolvidos no metabolismo do iodo. Previamente, nosso 
grupo descreveu uma paciente com a mutação V600E no gene BRAF no tumor 
primário e uma mutação nova (V600E+K601del) em metástases pareadas. 
Neste estudo, reportamos um carcinoma papilífero com um comportamento 
clínico incomum e correlacionamos com a presença de mutação no gene BRAF 
e os níveis de expressão de TSHR e NIS. Método: Análise de expressão dos 
genes NIS e receptor de TSH (TSHR) através da técnica de PCR em tempo real. 
Resultados: Descrevemos sete anos de acompanhamento de uma paciente jo-
vem que apresentava um tumor com comportamento agressivo e baixa res-
posta aos tratamentos convencionais. Uma acentuada diminuição da expressão 
do TSHR e a ausência de expressão de NIS foram observadas no tumor primário 
desta paciente quando comparada com o tecido tiroidiano normal adjacente. 
Conclusão: Nossos dados sugerem que as mutações encontradas nesta pa-
ciente no gene BRAF com conseqüente perda de expressão dos genes NIS e 
TSHR podem ter reduzido a captação de iodo radioativo e a resposta ao trata-
mento. (Arq Bras Endocrinol Metab 2008; 52/8:1313-1316)
Descritores: Carcinoma papilífero da tiróide; Mutação nos genes BRAF, NIS 
e TSHR
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INTRODUCTION
The activating point mutation V600E in exon 15 of BRAF gene is the most common and specifi c ge-
netic event in papillary thyroid carcinomas (PTC) (1,2). 
It has been suggested that BRAF V600E mutation is a 
prognostic biomarker that predicts poor outcome, as 
early recurrences are more frequent, tumors are less di-
fferentiated and have a lower survival rate (3-5). Some 
groups have suggested that its impact on clinical outco-
me may be associated with reduced expression of key 
genes involved in iodine metabolism 6. In fact, high risk 
of recurrence was associated with loss of NIS-mediated 
131I uptake (7). 
We have previously investigated BRAF mutational 
status in metastatic and non-metastatic papillary thyroid 
carcinomas (8,9). We have not only found an associa-
tion between BRAF-mutation and a more aggressive 
phenotype but also identifi ed a new BRAF mutation in 
tree lymph node metastases from PTC (8). In this stu-
dy we reported a seven-year follow-up in one of those 
patients where BRAF V600E was found in primary tu-
mor and V600E+K601del in matched lymph node me-
tastases. The uniqueness of this case is the combination 
of a juvenile papillary thyroid carcinoma which had lo-
cal recurrence and reduced 131I uptake and BRAF 
V600E mutation. Since loss of expression of iodine-
metabolizing genes may be associated with loss of their 
ability to trap 131I and less differentiate tumor, we in-
vestigated the TSHR and NIS expression in primary 
tumor and compared to matched-normal thyroid. 
SUBJECTS AND METHODS
Case report
An 18-year-old female was admitted to the Department 
of Endocrinology at Federal University of São Paulo in 
April 2001 after noticing a thyroid nodule (3,5cm) at 
the left lobe. Fine needle aspiration cytology (FNAC) 
was performed and cytological examination was sugges-
tive for papillary thyroid carcinoma. In July 2001 she 
underwent a total thyroidectomy and level VI lymph 
node dissection. Histological examination of the tumor 
assigned the diagnosis of classic papillary thyroid carci-
noma. Six lymph nodes presented metastasis of papillary 
thyroid carcinoma. According to American Joint Com-
mittee on Cancer Staging system tumor was classifi ed as 
pT2N1aMx (10). After surgery, 100-mCi 131I was admi-
nistered for therapeutic purposes and she presented a 
negative post dose 131I WBS (whole body scan). At that 
time, the TSH level was above 30 μIU/mL and serum 
thyroglobulin was 27 ng/mL. During follow-up the Tg 
remained 1.2-5.9 ng/mL under TSH suppression and 
she had negative neck ultrasound (US). At two-years 
follow up, ultrasound-guided FNA cytology revealed 
the presence of lymph node metastases. The patient un-
derwent surgery for lymph node dissection (levels II to 
V). Pathological fi ndings confi rmed the presence of me-
tastasis in 7 out of 18 lymph nodes. Four months after 
surgery, as she presented serum thyroglobulin 28.2 ng/
mL in hypothyroidism (TSH = 98 μIU/mL), she was 
treated with a high dose of radioiodine (450mCi). The 
post dose WBS showed a selective uptake at the anterior 
cervical region. In the last three years, Tg and anti-Tg 
antibody remained undetectable with suppressive L-T4 
therapy and negative cervical US. Since Tg remain unde-
tectable under TSH suppression, the patient performed 
a WBS and measurement of Tg under hypothyroidism 
(TSH =107 μIU/mL). WBS was negative and the Tg 
increased to 11.4 ng/mL The cervical US revealed a 
suspicious level IV lymph node in the right cervical side 
which was confi rmed by FNAC as a metastatic lymph 
node. The patient is expected to undergo her third sur-
gery. After that we will re-evaluate whether the patient 
should be treated with additional doses of radioiodine or 
if just thyroid suppressive therapy in the follow-up is the 
treatment of choice. 
All diagnostic procedures were performed in accor-
dance with the regulations of the local Ethics Committee. 
Written informed consent was obtained from the patient.
Molecular study
BRAF mutation screening was performed by direct se-
quencing at the RNA level (8). As described, this pa-
tient presented the BRAF V600E mutation in the 
primary tumor and the BRAF V600E+K6001del muta-
tion in the lymph node metastasis. At that time, distinct 
lymph node metastases were screened for BRAF muta-
tion and both, the new mutation and the V600E were 
found in different lymph node metastasis. 
As BRAF-mutated tumors were described as tu-
mors with no avidity for 131I uptake, as most of recur-
rences, we investigated the NIS and TSHR expression 
in primary tumor and matched-normal thyroid by 
quantitative PCR (qPCR). To this end, RNA extrac-
tion and cDNA synthesis was performed as described 
before (11). An aliquot of cDNA was used in a 20µL 
PCR reaction containing SYBR Green PCR Master 
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Mix (PE Applied Biosystems, Foster City, CA) and 200 
nM of each primer for the target or control gene (S8). 
Primers sequences were as follows: NIS sense: 5’ CA-
GAACCACTCCCGGATCAA 3’ and antisense: 5’ AC-
CCACCACAAAAGTCCAGAA 3’; TSH-R sense: 5’ 
ACATGACGTCAATCCCTGTG 3’ and antisense: 5’ 
TGAAAGCATATCCTTGGACTG 3’; S8 sense: 5’ AA-
CAAGAAATACCGTGCCC 3’ and antisense: 5’ 
GTACGAACCAGCTCGTTATTAG 3’. qPCR reac-
tions were performed in triplicate, the threshold cycle 
(Ct) was obtained using Applied Biosystem software 
and was averaged (SD ≤1). Gene expression was nor-
malized using the control gene ribosomal protein S8 as 
described before (9,12).
NIS and TSHR expression was markedly lower in 
primary tumor compared to matched normal thyroid 
(Figure 1). Although NIS and TSHR expression in 
lymph node metastases can not be evaluated as tissues 
are not available, the lack of 131I uptake may be a con-
sequence of loss of iodine-metabolizing genes (TSHR 
and NIS) already identifi ed in primary tumor. 
DISCUSSION
PTC usually shows a very good prognosis, however 10-
15% of patients are not cured after initial treatment. 
Identifying these high-risk patients at the time of diag-
nosis can help the choice of the most appropriate treat-
ment and follow-up for them (13). BRAF V600E 
mutations has been associated with poor prognosis fac-
tors, including extrathyroidal invasion, older age, lym-
ph node metastasis and advanced tumor stages (14,15). 
Recently, BRAF mutation was demonstrated to be a 
poor prognostic factor independent from other clinico-
pathological features (3,5). 
Here, we reported a papillary thyroid carcinoma 
patient diagnosed at age of 18 years with a lymph node 
metastasis at diagnosis, high rate recurrence, reduced 
uptake of 131I and BRAF mutation in both primary tu-
mor and different lymph node metastases. It is worth 
mentioning that although the BRAF V600E mutation 
is the most common genetic alteration in adult papilla-
ry thyroid carcinomas most of childhood or juvenile 
PTCs are usually BRAF mutation-free (16,17). 
These fi ndings, along with the fact that NIS expres-
sion was undetectable in the primary tumor, led us to 
hypothesize that her tumor may have lost the ability to 
trap 131I and evolutes to a less differentiated state due to 
loss of NIS expression. Moreover, the patient had a ma-
rkedly decrease of TSHR expression. Since for an effec-
tive thyroid ablation an adequate stimulation by TSH 
through thyroid hormone withdrawal or administra-
tion of recombinant human TSH is needed (18), we 
postulated that the loss of TSHR expression may also 
contribute to a high rate of recurrence and the reduced 
131I uptake. We must note that selective uptake occur-
red only at a highest dose administered (450mCi).
Although loss of TSHR in BRAF-mutated thyroid 
tumors was not found (6), we recently described a sig-
nifi cant correlation between the presence of BRAF 
V600E mutation and decrease of NIS and TSHR ex-
pression (19). 
This data not differ from those observed by Riesco-
Eizaguirre and cols. (7) in which PTC harboring BRAF 
V600E mutation had a more aggressive biological 
behavior characterized by early recurrences, tumors 
were less differentiated and had no response to 131I.
We hope that our data will contribute to an impor-
tant question that is whether assessment of BRAF sta-
tus can improve the management of thyroid cancer and 
to decide if a FDG-PET should be considered in these 
patients. However, whether kinase (MEK) inhibitors 
could be used as coadjutant of radioiodine therapy, due 
to their potential to restore iodine-metabolizing genes, 
remain an answered question. 
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Figure 1. Relative expression of NIS and TSHR determined by 
qPCR. Tissue samples consists of matched normal and tumor 
(PTC) tissues. Transcripts were normalized by control genes 
(S8) and Relative Expression was calculated as described in 
material and methods. 
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